Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan Is Only Just Beginning Its Biosimilars Journey

Says 2020 Will Be ‘Year Of Expansion’ For Biosimilars Program

Executive Summary

Despite having biosimilars of insulin glargine and etanercept that are expected to launch in the US and Europe respectively midway through this year, a biosimilar bevacizumab candidate filed in both regions, an in-development Botox rival still being considered and several other biosimilars already on the market around the world, Mylan insists that its biosimilars journey is just beginning.

You may also be interested in...



Viatris And FKB Introduce First Japanese Adalimumab Biosimilar

Viatris and Fujifilm Kyowa Kirin Biologics have introduced Japan’s first biosimilar rival to Humira.

Mylan’s Biosimilars Close In On $1bn Milestone

Mylan says it is closing in on $1bn in cumulative sales of its biosimilars, also disclosing its annual turnover figure from biosimilars as it reported its second-quarter results.

WHO Prequalifies More Biosimilars

The World Health Organization has recently added further biosimilar versions of trastuzumab to its list of prequalified products, along with Roche’s original trastuzumab and rituximab brands, Herceptin and MabThera/Rituxan.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149897

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel